Prophylaxis and treatment of thromboembolism have made one of the major impacts in medicine. Heparin has widely been used as the most effective drug during the last 50 years. However, its potential side effects have led to the search for equally effective but safer alternatives. At present, the low-molecular-weight heparins are the most promising steps in this direction. Considerable interest has been generated at the same time in exploring other gly cosaminoglycans of the nonheparin type for therapeutic use. The existence of these com pounds has been known for a long time and substantial information has been gathered on glycosaminoglycans such as heparinsulfate, dermatansulfate, and chondroitinsulfate. Many of these substances are derived from animal or plant sources, and some of them have now been synthesized. The aim of the Fourth Symposium on Glycosaminoglycan Research at Villa Vigoni in Loveno at Lake Comolltaly was to summarize the considerable new information in this field. The articles of the present volume are mainly based on a German-Italian collaboration supported by the Vigoni Program. The selected articles describe many different, nonheparin glycosaminoglycans, some of them already in clinical trials as antithrombotic agents. In particular, the interaction of glycosaminoglycans with some cellular elements of blood, especially leukocytes and platelets, are discussed. New methods for their identification and assays are described and considerable emphasis is placed on the pharmacokinetic aspects of these new compounds. Particularly, some nonanticoagulant activities of the glycosamino glycans are discussed in detail.
Sprache
Verlagsort
Verlagsgruppe
Illustrationen
Dateigröße
ISBN-13
978-1-4613-0371-8 (9781461303718)
DOI
10.1007/978-1-4613-0371-8
Schweitzer Klassifikation
1. Inequivalence of Glycosaminoglycans Using High-Performance Size Exclusion Chromatography, Polyacrylamide Gel Electrophoresis and High-Performance Capillary Electrophoresis.- 2. New NMR Spectroscopic Approaches for Structural Analysis of Glycosaminoglycans.- 3. Application of Mass Spectrometry to the Analysis of Natural and Synthetic Sulfated Oligosaccharides.- 4. Monoclonal Antibody Directed against Heparin and Heparin-Fractions.- 5. Simulation of Glycosaminoglycan Structures by Chemical Modifications of E. coli Polysaccharides K5 and K4.- 6. Pharmacology of Synthetic and Biotechnology-Derived Homologues and Analogues of Heparin.- 7. Protein Binding of Sulfated Glycosaminoglycans: Searching for Specificity.- 8. Non-Anticoagulant Actions of Glycosaminoglycans: Protein Binding Studies.- 9. Binding of Glycosaminoglycans to Leukocytes Using Fluorescent Labeled GAG-Derivatives.- 10. Intact Biological Activity and Binding to Granulocytes of LMM-Heparin-Tyramine-Fitc.- 11. A Detailed Evaluation of the Structural and Biological Effects of Alkaline O-Desulfation Reactions of Heparin.- 12. Glycosaminoglycans and Related Structures as Potential Inhibitors for Erythrocyte Infection by Plasmodium falciparum Malaria.- 13. The Interaction of Basic Fibroblast Growth Factor (bFGF) with Heparan Sulfate Proteoglycans: Biochemical Bases and Biological Implications.- 14. Binding of 125I-bFGF to Rat Aortic Smooth Muscle Cells: Effect of Natural and Chemically Modified Heparins and Heparan Sulfates.- 15. Modulatory Role of Heparin and Heparan Sulfates on Angiogenesis.- 16. Involvement of Thrombin on GAGs Release in Different Cellular Systems.- 17. TFPI Release by GAGs and Its Role in Their Mechanism of Action.- 18. Biological Activities and Effects on the Platelet Aggregation of a Structurally Defined Curdlan Sulfate.- 19. Influence of Glycosaminoglycans on Natural Killer Cell Activity.- 20. Non-Anticoagulant Actions of Glycosaminoglycans (GAGs): The Therapeutical Approach to Alzheimer's Disease.- 21. Therapy with Glycosaminoglycans in Nephrology.
